Adlai Nortye Ltd.
ANLDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Buparlisib & Paclitaxel | Phase 3 | Head and Neck Cancer | - | - |
Frequently asked questions
What is in Adlai Nortye Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adlai Nortye Ltd.'s (ANL) pipeline across Phase 3. Its lead program is Buparlisib & Paclitaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adlai Nortye Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adlai Nortye Ltd. (ANL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANL biotech catalysts?→
Add ANL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adlai Nortye Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.